NASDAQ: IMRX - Immuneering Corporation

半年間の収益性: +113.76%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Immuneering Corporation

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2021-07-30
ISIN US45254E1073
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://immuneering.com
Цена ао 2.39
1日あたりの価格変動: +6.88% (2.18)
週ごとの価格変動: +16.5% (2)
月ごとの料金変更: +9.39% (2.13)
3ヶ月間の価格変動: -12.41% (2.66)
半年間の価格変動: +113.76% (1.09)
年間の価格変動: -68.3% (7.35)
3年間の価格推移: -88.9% (20.99)
5年間の価格推移: 0% (2.33)
10年間の価格推移: 0% (2.33)
年初からの価格変動: +20.1% (1.94)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 467155.72 1
P/BV 2.35 6
P/E 0 0
EV/EBITDA -2.73 0
合計: 3.5

効率

名前 意味 学年
ROA, % -52.12 0
ROE, % -59.03 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0774 10
合計: 8.6

成長の衝動

名前 意味 学年
収益性 Revenue, % -99.98 0
収益性 Ebitda, % 695.35 10
収益性 EPS, % 100.27 10
合計: 8
さらに詳しく

機関 音量 共有, %
Cormorant Asset Management, LP 4204364 14.36
Price (T.Rowe) Associates Inc 3378100 11.54
Blackrock Inc. 2097406 7.16
Citadel Advisors Llc 2078092 7.1
Vanguard Group Inc 1073815 3.67
FMR, LLC 489447 1.67
Goldman Sachs Group Inc 457059 1.56
Geode Capital Management, LLC 444233 1.52
State Street Corporation 373662 1.28
HighVista Strategies LLC 254513 0.87

ETF 共有, % 年間の利益率, % 配当金, %
Range Cancer Therapeutics ETF 1.07445 47.24 0.11955
iShares Micro-Cap ETF 0.01885 17.09 1.54048



スーパーバイザー 役職 支払い 生年
Dr. Benjamin J. Zeskind M.B.A., Ph.D. Co-Founder, President, CEO & Director 935.09k 1983 (42 年)
Dr. Brett M. Hall Ph.D. Chief Scientific Officer 905.41k 1969 (56 年)
Ms. Mallory Morales CPA Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer N/A 1984 (41 年)
Ms. Paula George CPA Director of Accounting & Operations and Assistant Corporate Controller N/A
Mr. Michael D. Bookman J.D. Chief Legal Officer & Secretary N/A 1987 (38 年)
Ms. Leah R. Neufeld Chief People Officer N/A 1973 (52 年)
Dr. Peter King Ph.D. Head of Discovery & VP N/A
Dr. Praveen Nair Ph.D. Head of Translational Pharmacology & VP N/A
Mr. Harold E. Brakewood Chief Business Officer 579.77k 1966 (59 年)
Mr. Robert J. Carpenter M.B.A., M.S. Co-Founder & Chair Emeritus 75.36k 1946 (79 年)

住所: United States, Cambridge. MA, 245 Main Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://immuneering.com